Biotech Values

[kcalt]

Dew - IDIX Question:

<5. Comparative efficacy of ifn+NM283 vs ifn+ribavirin (Yarone Werber please take note): In phase-2/phase-3 trials in the peer-reviewed literature, ifn+riba produced viral clearance at 12 weeks by the Amplicor test in 38-57% of patients, while the clearance rate was 66% in the 200mg arm of the phase-2b NM283 arm reported at EASL last weekend.>

Which limit are they using for viral clearance? In the EASL data I'm seeing this:

"At 12 and 16 weeks, 71 percent and 73 percent, respectively, of patients in the 200 mg/day arm reached undetectable virus levels below 600 copies/mL compared to 73 percent and 74 percent in the pooled 800 mg/day arms. After 12 and 16 weeks, 45 percent and 62 percent, respectively, of patients in the 200 mg/day arm reached undetectable virus levels below 20 copies/mL..."